Solanezumab does not slow cognitive or functional decline in persons with amyloid deposition but normal cognition

Clinical Question

Do patients with amyloid deposition but no evidence of dementia benefit from taking solanezumab for 4.5 years?

Bottom line

Solanezumab did not prevent impairment of cognition, memory, or function in persons with amyloid deposition but largely normal cognition, even after 4.5 years. 1b

Study design: Randomized controlled trial (double-blinded)

Funding: Industry + govt

Setting: Outpatient (any)

Reviewer

Mark H. Ebell, MD, MS
Professor
University of Georgia
Athens, GA


Discuss this POEM


Comments

Arup Kumar Dhara

Impact assessment

Excellent

Anonymous

Alzhiemer's

medication intervention